<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089244</url>
  </required_header>
  <id_info>
    <org_study_id>GGN-CP4</org_study_id>
    <nct_id>NCT01089244</nct_id>
  </id_info>
  <brief_title>FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma</brief_title>
  <official_title>Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging
      and FET-PET in their ability to provide an accurate histological evaluation of low grade
      glioma and to reveal focal abnormalities within a homogeneously appearing tumor.
      Additionally, therapeutic effects should be assessed during a time period of two years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Astrocytoma</condition>
  <condition>Oligoastrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients with a suspected WHO II low grade glioma, disease progression within
1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients with a suspected WHO II low grade glioma, progression free within 1 year</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      High molecular wight DNA and RNA speciments for MGMT promoter methylation, IDH1/IDH2 and p53
      mutation, LOH 1p and 19q analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a suspected referred to a Neurosurgical Department in order to provide a
        diagnosis and therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma
             WHO II, Oligoastrocytoma WHO II)

          -  histological verification will be obtained either by microsurgery or by stereotactic
             biopsy

          -  patients older than 18 years

          -  Karnofsky Performance Score &gt;=70

          -  pregnant or nursing female patients will not be included in this study

        Exclusion Criteria:

          -  patients in whom informed consent cannot be obtained due to organic brain syndrome or
             insufficient language skills

          -  patients who cannot lie quiet for a time period of app. two hours during the FET-PEt
             scan

          -  medical history of a metastatic brain disease

          -  patients in whom an MRI scan cannot be performed due to claustrophobia metallic
             protheses or pacemakers etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg C. Tonn, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, LMU Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Munich, Department of Neurosurgery</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Bogdana Suchorska</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Low grade glioma</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Molecular imaging</keyword>
  <keyword>FET PET</keyword>
  <keyword>Therapy monitoring</keyword>
  <keyword>Temodar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

